KANSAS CITY, Kan. and BOSTON, Oct. 1, 2013 /PRNewswire/ -- Aratana Therapeutics (Nasdaq: PETX), a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets (pet therapeutics), today announced it was added to the Russell 2000 Index, Russell 3000 Index, Russell Global Index and Russell Microcap Index as part of Russell Investments' quarterly index adjustment on September 30, 2013.
Russell Investments conducts quarterly updates to its indexes to account for qualifying initial public offerings that occur following its annual mid-year index reconstitution, determining membership for its equity indexes primarily by objective, rules-based market-capitalization rankings and style attributes. Membership in the Russell 2000, which remains in place for one year, is based on membership in the broad-market Russell 3000 Index. The Russell 3000 also serves as the U.S. component to the Russell Global Index. Membership in the Russell Indexes means automatic inclusion in the appropriate growth and value style indexes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. Approximately $4.1 trillion in assets currently are benchmarked to them.
About Russell: Russell Indexes is part of Russell Investments (Russell), a global asset manager and one of only a few firms that offers actively managed multi-asset portfolios and services that include advice, investments and implementation. Russell stands with institutional investors, financial advisors and individuals working with their advisors—using the firm's core capabilities that extend across capital market insights, manager research, portfolio construction, portfolio implementation and indexes to help each achieve their desired investment outcomes.
About Aratana Therapeutics Aratana Therapeutics is a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, or pet therapeutics. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. Aratana's strategy is to in-license proprietary compounds from human biopharmaceutical companies and to develop these product candidates into therapeutics specifically for use in pets. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.
Contacts: Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (investors) firstname.lastname@example.org; (212) 375-2664
Andrew Mielach (media) email@example.com; (212) 375-2694
SOURCE Aratana Therapeutics